Last reviewed · How we verify
PF-06852231
At a glance
| Generic name | PF-06852231 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease (PHASE1)
- PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06852231 CI brief — competitive landscape report
- PF-06852231 updates RSS · CI watch RSS
- Pfizer portfolio CI